Treprostinil for Pulmonary Hypertension Treatment Patent

ChangeBridge: EPO Bulletin - Medical Devices (A61M)

Published March 18th, 2026

Detected March 23rd, 2026

Summary

The European Patent Office has published patent EP4710972A2 for a Treprostinil treatment method for pulmonary hypertension. The patent, filed by InvoX Belgium NV, describes a two-stage aerosolized administration using a soft mist inhaler with increasing concentrations.

View original document View source feed page

What changed

The European Patent Office (EPO) has published patent application EP4710972A2, detailing a novel method for treating pulmonary hypertension using Treprostinil. The patent, assigned to InvoX Belgium NV, outlines a treatment regimen involving two distinct aerosolized administrations of Treprostinil via a soft mist inhaler. The key innovation lies in the second administration having a higher concentration of Treprostinil than the first, intended for sequential treatment periods.

This publication represents a new intellectual property filing concerning a specific pharmaceutical treatment. While it does not impose direct regulatory obligations on manufacturers or healthcare providers, it signifies a potential future product or therapeutic approach. Companies involved in pulmonary hypertension treatments or Treprostinil formulations should be aware of this patent for competitive intelligence and potential licensing considerations. No immediate compliance actions are required, as this is a patent publication, not a regulatory approval or rule.

Source document (simplified)

← EPO Patent Bulletin

TREPROSTINIL FOR THE TREATMENT OF PULMONARY HYPERTENSION

Publication EP4710972A2 Kind: A2 Mar 18, 2026

Applicants

InvoX Belgium NV

Inventors

D'OREY MARCHAND SEQUEIRA LOPES BEIRÃO BELO, Isabel, RAWERT, Jürgen

Abstract

The invention provides Treprostinil or a pharmaceutically acceptable salt or derivative thereof for use in a method of treatment of pulmonary hypertension in a subject being diagnosed with pulmonary hypertension or being at risk of developing pulmonary hypertension wherein the treatment comprises the steps of
i) administering to said subject a first liquid composition comprising Treprostinil or a pharmaceutically acceptable salt or derivative thereof in a first concentration in aerosolized form for a first treatment period, and
ii) administering to said subject a second liquid composition comprising Treprostinil or a pharmaceutically acceptable salt or derivative thereof in a second concentration in aerosolized form for a second treatment period following the first treatment period;

wherein the second concentration of Treprostinil or a pharmaceutically acceptable salt or derivative thereof in the second liquid composition is higher than the first concentration of Treprostinil or a pharmaceutically acceptable salt or derivative thereof in the first liquid composition, and
wherein the first and the second liquid compositions are aerosolized and administered to the subject using a soft mist inhaler.

IPC Classifications

A61M 11/00 20060101AFI20230728BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →